2-t-Butyl-5-ethyl-1,3,4-thiadiazol | 41398-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-t-Butyl-5-ethyl-1,3,4-thiadiazol
• 英文别名: 2-tert-butyl-5-ethyl-[1,3,4]thiadiazole；2-Tert-butyl-5-ethyl-1,3,4-thiadiazole
• CAS: 41398-04-3
• 化学式: C₈H₁₄N₂S
• 分子量: 170.279
• InChiKey: FUPQEIACBSVTCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,2-dimethyl-propionic acid N'-propionyl-hydrazide 在 tetraphosphorus decasulfide 作用下， 生成 2-t-Butyl-5-ethyl-1,3,4-thiadiazol
  参考文献：
  名称：

  Lund,H., Acta Chemica Scandinavica (1947), 1973, vol. 27, p. 391 - 395

  摘要：

  DOI：

文献信息

• FUSED HETEROCYCLYC INHIBITOR COMPOUNDS
  申请人：Melvin, JR. Lawrence S.

  公开号：US20100029638A1

  公开（公告）日：2010-02-04

  The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  本发明提供了一种具有组蛋白去乙酰化酶（HDAC）和/或 Cyclin 依赖性激酶（CDK）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。
• NITROGEN-CONTAINING HETEROARYL DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20110183979A1

  公开（公告）日：2011-07-28

  The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及式(I)的新氮杂芳基衍生物，其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述，以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A，并可作为药物使用。
• PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：LASSALLE Gilbert

  公开号：US20130005724A1

  公开（公告）日：2013-01-03

  The present invention relates to derivatives of pyridino-pyridinones, and to their preparation and use thereof, having activity as inhibitors of kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand receptors, said derivatives comprising compounds of formula (I): wherein the various substituent groups are more specifically defined herein. The compounds are suitable as therapeutics for the treatment of various proliferative diseases.

  本发明涉及吡啶基吡啉酮的衍生物，以及其制备和使用，具有作为PDGF（血小板源性生长因子）配体受体的激酶活性抑制剂以及可选的FLT3（类似于酪氨酸激酶受体）配体受体的激酶活性抑制剂的活性，所述衍生物包括化合物的结构如下（I）：其中各种取代基在此更具体地定义。这些化合物适用于治疗各种增生性疾病。
• PROTEIN KINASE INHIBITORS
  申请人：Bearss David J.

  公开号：US20080207632A1

  公开（公告）日：2008-08-28

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , X, Z, L 2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了蛋白激酶抑制剂，其在治疗蛋白激酶介导的疾病和病状中具有功效，例如癌症，如Aurora激酶表达的癌症和Axl激酶表达的癌症。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中R1、R2、R3、X、Z、L2和w如本文所定义。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• RHO KINASE INHIBITORS
  申请人：KIRRANE Thomas Martin

  公开号：US20120270868A1

  公开（公告）日：2012-10-25

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3和X的定义如本文所述。本发明还涉及包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。